Drugs / BGB-3245
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06194877 | Apr 2024 → Mar 2025 | colorectal cancer, pancreatic ductal adenocarcinoma | MapKure, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT04249843 | Feb 2020 → Aug 2025 | cancer | MapKure, LLC | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05580770 | Feb 2023 → Jan 2025 | neoplasm | SpringWorks Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-3245 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05580770 ↗ |
| Route | Oral | “BGB-3245 administered orally (PO)” NCT04249843 ↗ |